CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML). The main study has completed enrollment.In Sub-studies 1 and 2...
Phase 1, Phase 2
Seattle, Washington, United States of America and 55 other locations
treating measurable residual disease in patients with acute myeloid leukemia. Gemtuzumab ozogamicin is a monoclonal antibody, called gemtuzu...
Phase 2
Seattle, Washington, United States
allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care in patients with Active, Relapsed or Refractory Acute Myeloid Leukemia...
Phase 3
Seattle, Washington, United States of America and 23 other locations
This study is evaluating the safety and efficacy of a new BTK inhibitor, acalabrutinib, for the treatment of chronic lymphocytic leukemia (C...
Phase 1, Phase 2
Seattle, Washington, United States and 11 other locations
A Phase 1 first-in-human dose-escalation and dose-expansion study of BMF-500, an oral FLT3 inhibitor, in adult patients with acute leukemia....
Phase 1
Seattle, Washington, United States and 13 other locations
works in treating medically less-fit patients with acute myeloid leukemia or other high-grade myeloid neoplasms. Drugs used in chemotherapy,...
Phase 2
Seattle, Washington, United States
This is an open-label, multicenter, Phase 1b/2 study to determine the safety and tolerability of IMGN632 and assess the antileukemia activity of IMGN...
Phase 1, Phase 2
Seattle, Washington, United States of America and 28 other locations
The main objective of this study is to evaluate the safety and efficacy of SC blinatumomab in children below 12 years of age.
Phase 1, Phase 2
Seattle, Washington, United States and 2 other locations
participants with previously treated chronic phase - chronic myeloid leukemia (CP-CML).The study has two parts: Part 1 of the trial (Dose Es...
Phase 1, Phase 2
Seattle, Washington, United States and 53 other locations
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia ...
Phase 3
Seattle, Washington, United States and 37 other locations
Clinical trials
Research sites
Resources
Legal